Unwanted drug effects were noted in two patients (patient 12 and 13), both on the salbutamol day. There were complaints of tremors and headaches that were considered to be moderately severe. In all other patients except patient 12 (who felt unwell after the last formoterol dose), these high doses of p-mimetics were impressively well tolerated. antibiotic levaquin
The principal aim of this study was to find the dose of formoterol from an MDI that would bring about a maximal bronchodilatory effect that could be measured. For this reason, a cumulative dosage scheme was put forward in which salbutamol from an MDI was used as a comparator, at the same time as the “gold standard.” In the knowledge that the peak bronchospasmolytic effect of salbutamol was reached after approximately 1 hour, it was decided that successive doses of both drugs would take place at hourly intervals. We were expecting to find a peak bronchospasmolytic effect from the formoterol between 60 and 120 minutes after inhalation. Because the bronchospasmolytic effect of inhaled formoterol lasted longer, and because significant bronchospasmolysis (FE Vi values 20 percent or more above the basal level) could be observed up to 12 hours after dosage, one might have expected that the effect of the first dose of formoterol would still be noticeable after the last planned drug dose 5 hours later (Fig 1).